M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 28.14 CNY -0.95% Market Closed
Market Cap: 12.1B CNY

Mayinglong Pharmaceutical Group Co Ltd's latest stock split occurred on Jul 21, 2015

The company executed a 13-for-10 stock split, meaning that for every 10 shares held, investors received 13 new shares.

Before the split, Mayinglong Pharmaceutical Group Co Ltd traded at 31.6 per share. Afterward, the share price was about 24.6531.

The adjusted shares began trading on Jul 21, 2015. This was Mayinglong Pharmaceutical Group Co Ltd's 5th stock split, following the previous one in May 20, 2011.

Last Splits:
Jul 21, 2015
13-for-10
May 20, 2011
2-for-1
Jun 12, 2009
9-for-5
Jun 4, 2008
3-for-2
May 31, 2007
6-for-5
Pre-Split Price
22.4157 31.6
Post-Split Price
24.6531
Before
After
Last Splits:
Jul 21, 2015
13-for-10
May 20, 2011
2-for-1
Jun 12, 2009
9-for-5
Jun 4, 2008
3-for-2
May 31, 2007
6-for-5

Mayinglong Pharmaceutical Group Co Ltd
Stock Splits History

Mayinglong Pharmaceutical Group Co Ltd Stock Splits Timeline
Jul 21, 2015
Jul 21, 2015
Split 13-for-10
x1.3
Pre-Split Price
22.4157 31.6
Post-Split Price
24.6531
Before
After
May 20, 2011
May 20, 2011
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
10.2372
Before
After
Jun 12, 2009
Jun 12, 2009
Split 9-for-5
x1.8
Pre-Split Price
N/A
Post-Split Price
10.2372
Before
After
Jun 4, 2008
Jun 4, 2008
Split 3-for-2
x1.5
Pre-Split Price
N/A
Post-Split Price
10.2372
Before
After
May 31, 2007
May 31, 2007
Split 6-for-5
x1.2
Pre-Split Price
N/A
Post-Split Price
10.2372
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.17 45.17 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
59.43 59.43 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
12.1B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
33.8 CNY
Undervaluation 17%
Intrinsic Value
Price
M
Back to Top